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Regorafenib monotherapy is a potential option for metastatic colorectal cancer patients. However, 
the lack of predictive factors and the severe toxicities related to treatment have made its use in 
clinical practice challenging. Polymorphisms of VEGF and its receptor (VEGFR) genes might regulate 
angiogenesis and thus potentially influence outcome during anti-angiogenesis treatment such as 
regorafenib. Aim of our study was to evaluate the role of VEGF and VEGFR genotyping in determining 
clinical outcome for colorectal cancer patients receiving regorafenib. We retrospectively collected 
clinical data and samples (tumour or blood) of 138 metastatic colorectal cancer patients treated 
with regorafenib. We analysed the correlation of different VEGF-A, VEGF-C and VEGFR-1,2,3 single 
nucleotide polymorphisms (SNPs) with patients’ progression-free survival (PFS) and overall survival 
(OS). Results from angiogenesis genotyping showed that only VEGF-A rs2010963 maintained an 
independent correlation with PFS and OS. Among clinical factors only ECOG PS was independently 
correlated with OS, whereas no correlation with PFS was evident. Grouping together those results 
allowed further patients stratification into 3 prognostic groups: favourable, intermediate and 
unfavourable. VEGF-A rs2010963 genotyping may represent an important tool for a more accurate 
selection of optimal candidates for regorafenib therapy.
Regorafenib is a potential option in heavily pre-treated metastatic colorectal cancer patients. This drug has proven 
its efficacy in the CORRECT and CONCUR trials1,2 as well as in the observational analyses CONFIRM and 
REBECCA3,4.
Available data suggest that only approximately 50% of patients treated might obtain a clinical benefit from 
regorafenib in the face of a not negligible proportion of potentially harmful side effects. Therefore the identifica-
tion of patients who are more likely to benefit from this treatment would also spare unnecessary side effects in 
those who do not gain any clinically meaningful benefit from the drug.
Differently from anti-EGFR monoclonal antibodies for which we have a well-established selection criterion 
with the evaluation of RAS mutational status (K-ras, N-ras: rat sarcoma viral oncogene homologous; K stands 
for Kirsten, N stands for Neural)5,6, results for anti-angiogenic treatment options, including regorafenib, are still 
conflicting7. The inhibition of tumour angiogenesis, primarily based on the vascular endothelial growth factor 
(VEGF)-driven pathway, is one of the primary mechanisms of action of regorafenib treatment. A growing body 
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of evidence suggested a possible correlation between an altered expression of the angiogenetic pathway identified 
through polymorphisms analysis and global outcome in colorectal, gastric, breast, ovarian, renal cell and hepa-
tocellular patients treated with drugs directed against tumour neoangiogenesis8,9. Remarkably all known VEGF 
polymorphisms are not located in the coding region, therefore different biological mechanisms in influencing 
gene expression and then clinical outcome have been proposed10,11. Many molecular events ultimately leading 
to tumour neoangiogenesis have been in fact linked to SNPs in the VEGF and VEGF receptor (VEGFR) genes. 
Several SNPs in the promoter, 5- and 3-untranslated regions (UTRs) are present in the VEGF family.
In the present analysis we evaluated the potential role of VEGF and VEGFR polymorphisms in regorafenib 
treated colorectal cancer patients in order to define specific subgroups more likely to benefit from such a treat-
ment approach.
Results
Patients’ characteristics. One hundred and thirty-eight patients were eligible for analysis: 76 males (55%) 
and 62 females (45%), median age was 63 years (33–78). Seventy patients (51%) were K-RAS or RAS wild type. 
Most of the patients had an ECOG PS (Eastern Cooperative Oncology Group-Performance Status) 0 at the time of 
start of regorafenib (84%) and the majority of them received at least 4 previous lines of treatment (96 patients, 70%).
In the whole population median OS was 7.3 months while median PFS was 2.4 months. Forty-two patients 
(30%) obtained disease stabilization whereas the remaining 96 patients (70%) progressed under treatment. Partial 
or complete responses were not observed in this group of patients.
Results of angiogenesis genotyping and clinical factors analysis. All SNPs genotyped presented 
an overall call rate of ≥ 90%. We have evaluated concentration and purity index of each sample by UV spectro-
photometry as the ratio absorbance 260/280 nm. All samples presented a purity index between 1.5 and 2.0. The 
frequencies of the tested genotypes resulted comparable to those reported in Caucasians, with no significant 
deviation from the Hardy–Weinberg equilibrium. Linkage disequilibrium (LD) was not observed.
Only VEGF-A rs2010963 (+ 405G > C) was associated with both OS and PFS. Twenty patients (14%) pre-
sented the CC homozygous genotype, whereas the remaining 118 patients (86%) harbored the GG or GC 
genotype.
In this group of patients median OS was 9 months vs. 6.5 months for CC homozygous patients vs. patients 
showing the GG or GC genotype (hazard ratio HR: 0.52, confidence interval 95%CI: 0.34–0.99, p = 0.049) [Fig. 1].
Median PFS in patients with the CC genotype vs. the remaining patients (GG or GC genotypes) was respec-
tively 2.2 vs. 1.8 months (HR: 0.49, 95%CI: 0.33–0.81, p = 0.0038) [Fig. 2].
In the 20 patients harboring the CC genotype, 11 (55%) patients obtained disease stabilization while 9 patients 
(45%) progressed under treatment. In the remaining 118 patients 31 (26%) experienced disease stabilization and 
the remaining 87 progressed while on treatment (74%). This difference in the disease control rate (DCR) was 
statistically significant (p = 0.02).
VEGF-R2 rs1870377 and VEGF-R3 rs307805 were both correlated to OS (but not PFS), whereas VEGF-R1 
rs664393 resulted linked to PFS only. Table 1 summarizes survival outcomes according to all polymorphisms 
tested.
Among clinical factors tested, ECOG PS resulted significantly associated with worse overall survival. In par-
ticular, in the 22 patients (16%) presenting with ECOG PS ≥ 1 vs. those presenting with an ECOG PS 0 (116, 
84%) median overall survival was respectively 4.1 months vs. 7.8 months (HR: 0.52, 95%CI: 0.21–0.81, p = 0.009) 
[Fig. 3]. Apparently ECOG PS was not able to influence PFS (median PFS 1.7 months vs. 1.9, HR: 0.75, 95%CI: 
0.41–1.24, p = 0.23) [Fig. 4].
Figure 1. Overall survival for patients with CC rs2010963 SNP (405 G->C) genotype (BLUE) vs patients 
with either GC or GG genotype (GREEN) (9.0 vs 6.5 months, HR: 0.52, 95%CI: 0.34–0.99, p = 0.04). 
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At multivariate analysis VEGF-A rs2010963 (p = 0.009) and ECOG performance status (p = 0.004) demon-
strated an independent role as predictive factors for overall survival whereas VEGF-R3 rs307805 and VEGF-R2 
rs1870377 resulted not significant. In particular, Exp(B) for ECOG performance status was 2.80 (95%CI:1.59–4.92) 
whereas Exp(B) for rs2010963 was 2.77 (95%CI:1.37–5.60).
On the contrary only VEGFA rs2010963 resulted independently correlated to PFS (p = 0.005). Major clinical 
characteristics according to VEGFA rs2010963 resulted comparable across different genotypes and to the whole 
patients population [Table 2].
Taken together ECOG performance status and VEGFA rs2010963 allowed a further patient stratification into 
3 groups with different clinical outcome during regorafenib: favourable group (both favourable VEGFA rs2010963 
genotype and ECOG PS 0), intermediate group (either favourable VEGFA rs2010963 genotype or ECOG PS 0) 
and unfavourable group (both unfavourable VEGFA rs2010963 genotype and ECOG PS ≥ 1). Fourteen patients 
(10%) were allocated in the favourable group, 108 patients (78%) were allocated in the intermediate group and 
16 patients (12%) were allocated in the unfavourable group. Median OS resulted progressively decreased across 
these groups (OS not reached, 7.8 and 3.9 months respectively in the favourable, intermediate and unfavourable 
group, p < 0.0001) [Fig. 5].
We also analysed the relative impact of each of the two factors on survival: in particular, patients were divided 
into 4 groups (ECOG PS 0 and CC genotype vs. ECOG PS 0 and GC or GG genotype vs. ECOG PS 1 or higher 
and the CC genotype vs. ECOG PS 1 or higher and the GC or GG genotype). When we analysed the impact of the 
four different groups on PFS, patients with the CC genotype, regardless of performance status, showed similar 
(and statistically comparable, HR:0.86, 95%CI:0.3834–1.9530) [Fig. 6]. On the contrary overall survival analysis 
showed that patients with ECOG PS 1 higher and the GC or GG genotype (16/138, 11%) had the worst survival 
among the 4 subgroups, whereas patients with ECOG PS 1 or higher and the CC genotype had comparable sur-
vival to patients with ECOG PS 0 and the GC or GG genotype [Fig. 7].
Discussion
The introduction of regorafenib for the treatment of heavily pre-treated metastatic colorectal cancer undoubtedly 
filled the clinical gap caused by the previous lack of valid options in this setting. Furthermore, the concept of sus-
tained angiogenesis inhibition in different lines of treatment for metastatic colorectal cancer patients who are not 
amenable to radical surgical resection proves to be effective in a series of already published works12–15.
The virtual absence of predictive factors for efficacy/resistance further restrained wide use of this treatment 
opportunity. The capability of regorafenib to pharmacologically interact with tumour-driven angiogenesis seems 
to indicate that this biological pathway may be a potentially relevant predictive factor for clinical outcome during 
therapy. However, recent analyses conducted on the cohort of patients enrolled in the CORRECT trial16 seemed 
to rule out a potential predictive role of soluble serum concentrations of various factors linked to neoangiogenesis 
(such as sVEGFR-1, VEGF-A, VEGF-C, angiopoietin-2 and others).
In our analysis we suggest that single nucleotide polymorphisms in the VEGF associated pathway may be 
linked to clinical outcome in patients treated with regorafenib. In particular the VEGFA rs2010963 resulted inde-
pendently associated with median OS and PFS and disease control rate thus suggesting a possibly effective way 
for patients selection in a non-negligible proportion of cases. The VEGF-A rs2010963 CC genotype that resulted 
linked to improved outcome is present in 14% of the population analysed.
The VEGF-A rs2010963 is located in the 5′ -UTR region, nearby the gene promoter region thus potentially 
influencing VEGF-A expression and resulting in an increased tumour angiogenesis. Many studies confirmed in 
fact a central role for the VEGF-A rs2010963 in biological systems either as a risk factor for human carcinogenesis 
or predictive factor for anti-angiogenesis therapy17.
Figure 2. Progression-free survival for patients with CC rs2010963 SNP (405 G->C) genotype (BLUE) 
vs. patients with either GC or GG genotype (GREEN) (2.2 vs. 1.8 months, HR: 0.49, 95%CI: 0.33–0.81, 
p = 0.003). 
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PFS p OS p
rs10434
 AA genotype (32, 23%) 1.82 months 6.51 months
 AG genotype (74, 54%) 2.01 months 7.89 months
 GG genotype (32, 23%) 1.92 months 0.14 4.67 months 0.21
rs2010963
 GG genotype (62, 44%) 1.84 months 7.89 months
 CG genotype (56, 41%) 1.94 months 5.95 months
 CC genotype (20, 15%) 4.28 months 0.0098 9.08 months 0.049
rs25648
 AA genotype (100, 72%) 1.94 months 6.51 months
 AT genotype (30, 22%) 1.91 months 7.99 months
 TT genotype (8, 6%) 2.02 months 0.96 9.38 months 0.18
rs3025039
 AA genotype (120, 87%) 1.91 months 7.63 months
 AT genotype (16, 12%) 3.12 months 5.72 months
 TT genotype (2, 1%) 1.84 months 0.24 3.55 months 0.06
rs699947
 CC genotype (44, 32%) 2.07 months 5.95 months
 AC genotype (56, 40%) 2.01 months 7.99 months
 AA genotype (38, 28%) 1.84 months 0.11 6.51 months 0.46
rs833061
 TT genotype (44, 32%) 2.07 months 5.95 months
 TC genotype (56, 40%) 2.01 months 7.99 months
 CC genotype (38, 28%) 1.84 months 0.11 6.51 months 0.46
rs4604006
 CC genotype (68, 49%) 1.84 months 7.8 months
 CT genotype (60, 43%) 1.97 months 5.95 months
 TT genotype (10, 8%) 3.75 months 0.50 13.16 months 0.34
rs7664413
 CC genotype (80, 58%) 1.84 months 7.8 months
 CT genotype (52, 38%) 1.97 months 5.95 months
 TT genotype (6, 4%) 3.75 months 0.41 NR 0.07
rs664393
 CC genotype (106, 77%) 2.01 months 6.97 months
 CT genotype (30, 22%) 1.84 months 8.72 months
 TT genotype (2, 1%) 1.48 months <0.0001 5.95 months 0.77
rs7993418
 genotype (68, 49%) 1.84 months 7.8 months
 AG genotype (64, 46%) 1.97 months 6.51 months
 GG genotype (6, 5%) 5.3 months 0.42 10.23 months 0.32
rs1870377
 TT genotype (72, 52%) 1.97 months 7.63 months
 AT genotype (62, 45%) 1.84 months 7.8 months
 AA genotype (4, 3%) 2.12 months 0.98 3.54 months 0.0061
rs2071559
 AA genotype (44, 32%) 1.84 months 6.51 months
 AG genotype (56, 40%) 1.94 months 7.8 months
 GG genotype (38, 28%) 2.07 months 0.86 5.92 months 0.80
rs2305948
 CC genotype (114, 83%) 1.94 months 7.63 months
 CT genotype (24, 27%) 1.84 months 7.8 months
 TT genotype (0, 0%) NA 0.88 NA 0.81
rs7667298
 CC genotype (40, 29%) 2.07 months 5.92 months
 CT genotype (62, 45%) 1.88 months 7.8 months
 TT genotype (36, 26%) 1.84 months 0.46 7.99 months 0.80
rs307805
Continued
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On the other hand different studies investigated the impact of VEGF-A rs2010963 on clinical outcome during 
anti-angiogenesis therapy. According to present results, in advanced HCC receiving sorafenib patients harbour-
ing the VEGF-A rs2010963 CC genotype showed a significantly improved overall and progression free survival9.
PFS p OS p
 AA genotype (106, 77%) 1.91 months 7.63 months
 AG genotype (30, 22% 2.07 months 8.75 months
 GG genotype (2, 1%) 2.3 months 0.83 3.52 months 0.0492
rs6877011
 CC genotype (110, 80%) 1.97 months 6.97 months
 CG genotype (28, 20%) 1.86 months 7.8 months
 GG genotype (0, 0%) NA 0.42 NA 0.48
rs307822
 CC genotype (104, 75%) 1.97 months 6.97 months
 CT genotype (34, 25%) 1.84 months 7.8 months
 TT genotype (0, 0%) NA 0.08 NA 0.67
Table 1.  Impact of different genotypes on overall survival and progression free survival (in bold where 
statistically significant).
Figure 3. Overall survival for patients with ECOG:0 status (BLUE) vs patients with ECOG:1 or more status 
(GREEN) (7.8 months vs 4.1 months, HR: 0.52, 95%CI:0.21–0.81, p = 0.009). 
Figure 4. Progression-free survival for patients with ECOG:0 status (BLUE) vs patients with ECOG:1 or 
more status (GREEN) (1.9 vs 1.7 months, HR: 0.75, 95%CI: 0.41–1.24, p = 0.23). 
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Whether VEGF-A rs2010963 in our analysis may represent a prognostic or predictive factor is matter of 
debate. On the one hand the absence of a control group make this distinction very challenging, but on the other 
hand the impact on PFS and DCR seems to indicate a predictive more than a prognostic role.
The ECOG PS is an important prognostic indicator and a powerful driver for strategy decision in advanced 
colorectal cancer patients. In our analysis patients presenting with an ECOG PS 0 seemed to benefit the most 
from regorafenib treatment. However in this case the ECOG PS did not correlate with PFS or DCR thus sug-
gesting a more pronounced prognostic impact. Interestingly patients with ECOG PS 1 or higher showing the 
rs2010963 CC polymorphism still demonstrated an improved prognosis compared with those with ECOG PS 1 
or higher, but who had the rs2010963 GC or GG polymorphism. We can then speculate that in patients harbour-
ing the rs2010963 CC polymorphism the improvement in prognosis seemed independent from ECOG PS and 
hypothetically related to a true susceptibility of the tumour to regorafenib therapy.
Accordingly at the multivariate analysis for overall survival both factors (ECOG PS and rs2010963 polymor-
phisms) showed not only an independent role, but also a comparable influence in determining overall survival (as 
it can be assumed by the similar results of Exp(B) at multivariate analysis for both factors).
Coupling results from VEGF-A rs2010963 and ECOG PS led us to further characterize different patients’ 
groups with different outcomes during regorafenib.
Total
rs2010963 CC 
homozygous
Rs2010963 GG 
homozygous - 
heterozygous p
138 20 (14%) 118 (86%)
Sex
 Male 76 (55%) 10 (50%) 66 (56%)
 Female 62 (45%) 10 (50%) 52 (44%) 0.90
Median Age (range) 63 (33–78) 56 (42–71) 62 (33–78)
 ≤ 70 110 (80%) 18 (90%) 92 (78%)
 > 70 28 (20%) 2 (10%) 26 (22%) 0.34
K-RAS status
 Wild Type 70 (51%) 13 (65%) 57 (48%)
 Mutant 68 (49%) 7 (35%) 61 (52%) 0.25
ECOG PS
 0 116 (84%) 14 (70%) 102 (86%)
 ≥ 1 22 (16%) 6 (30%) 16 (14%) 0.12
Previous treatment lines
 3 or less 42 (30%) 4 (20%) 38 (32%)
 4 or more 96 (70%) 16 (80%) 80 (68%) 0.40
Table 2.  Patients’ clinical characteristics according to rs2010963 genotyping.
Figure 5. Median overall survival for patients in the favourable group (VEGF-A rs2010963 CC genotype 
SNP and ECOG PS 0) (BLUE) vs. patients in the intermediate group (either VEGF-A rs2010963 CC 
or ECOG PS 0 status (GREEN) vs. patients in the unfavourable group (VEGF-A rs2010963 CG or GG 
genotype and ECOG PS ≥1) (ORANGE) (NR vs. 7.8 months vs. 3.9 months, p < 0.0001). 
www.nature.com/scientificreports/
7Scientific RepoRts | 6:25195 | DOI: 10.1038/srep25195
In particular patients showing an unfavourable profile (both unfavourable VEGFA rs2010963 genotype and ECOG 
PS ≥ 1) seemed to derive little or no benefit from the use of regorafenib. In this group of patients a more than usual careful 
evaluation of both the risk-to-benefit ratio and patients expectations from therapy should drive the treatment decision.
Figure 6. Median PFS for patients stratified accordingly to 4 different subgroups: PS0 and CC homozygous 
subtype (BLUE) vs. PS0 and GC or GG homozygous subtype (GREEN) vs. PS1+ and CC homozygous 
subtype (ORANGE) vs. PS1+ and GC or GG homozygous subtype (BLACK). 
Figure 7. Median OS for patients stratified accordingly to 4 different subgroups: PS0 and CC homozygous 
subtype (BLUE) vs. PS0 and GC or GG homozygous subtype (GREEN) vs. PS1+ and CC homozygous 
subtype (ORANGE) vs. PS1+ and GC or GG homozygous subtype (BLACK). 
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There is a series of considerations that have to be made regarding the limits of our analysis: the retrospective 
nature of our analysis, in absence of a “control group” who did not receive regorafenib, is unable to fully establish 
the prognostic or truly predictive (or perhaps both) nature of the markers used.
Another important consideration is that, when looking at the result concerning progression-free survival, 
even though median progression free survival was significantly different between patients with favourable 
VEGF-A rs2010963 genotype when compared with the other subset (2.2 vs. 1.8 months), the difference in the risk 
of progression was truly evident only after 2 months of observation time, with about 40% of patients who directly 
progressed at the first radiological evaluation regardless of their VEGF genotype profile: this fact suggests that 
factors other than VEGF pathway genotyping may be crucial in determining the efficacy of regorafenib treatment.
A further relevant consideration is about the relatively small number of patients who would be allocated into 
either prognostic group (favourable and unfavourable) according to our findings. In particular, patients with the 
favourable subgroup would represent about 10% of the patients treated, compared with 10–12% of patients in the 
unfavourable subgroup.
In clinical trials investigating regorafenib monotherapy for metastatic colorectal cancer patients, the propor-
tion of patients who truly benefited from treatment (i.e. with a PFS longer than 6 months) was about 10–12%1–3. 
At the same time, the proportion of patients showing a PFS shorter than 2 months in all these trials taken together 
is once again about 10–12%. These proportions are strikingly similar to those observed in our analysis, thus 
suggesting that we could individuate 3 groups of patients among those treated with regorafenib. A small number 
of patients deriving the highest benefit from the drug with the longest progression free survival, a further small 
group of patients who does not derive any clinical benefit from treatment and, due to rapid disease progression, 
usually stops treatment very soon and progresses shortly thereafter, and, last, the rest of the patients with inter-
mediate characteristics.
We believe that after validation in a larger, hopefully prospective, series of metastatic colorectal cancer 
patients, VEGF-A rs2010963 may represent an important tool for a more accurate selection of patients poten-
tially candidates for regorafenib. This selection opportunity will ultimately improve the therapeutic index of such 
a treatment approach by limiting treatment to potentially responding patients and sparing unnecessary toxicity 
to those unlikely to benefit.
Methods
Patients Selection. The ALICE-3 (Angiogenesis lInked coLorectal CancEr) is a retrospective multicen-
tre study. All consecutive histologically-proven metastatic colorectal cancer patients, previously treated with all 
standard chemotherapy-regimens (oxaliplatin, irinotecan, 5FU, bevacizumab and either cetuximab or panitu-
mumab in case of K-RAS, and then RAS, wild type status) receiving regorafenib monotherapy were eligible for 
our analysis.
All patients started treatment with regorafenib at the dose of 160 mg/die (day 1 to 21 every 28 days), dose 
reduction was applied as clinically indicated. Tumour response was evaluated every 8 weeks by clinicians’ assess-
ment and according to the response evaluation criteria for solid tumours (RECIST). Written informed consent 
was obtained for all patients enrolled into the analysis and the study was approved by the Ethical Committee of 
the Azienda Ospedaliera Universitaria of Ancona, Italy. The methods were carried out in accordance with the 
approved guidelines.
VEGF and VEGFR genotyping. VEGF and VEGFR genotyping was performed using DNA extracted from 
formalin-fixed paraffin-embedded tissue blocks of metastatic colorectal carcinoma or from whole blood.
For tissue blocks, paraffin wax was removed with xylene and the samples were washed twice with 100% etha-
nol. DNA was isolated from the deparaffinised tissue using the RecoverAll™ Total Nucleic Acid Isolation Kit for 
(formalin fixed paraffin embedded) Tissues (Applied Biosystems, Foster City, CA, USA), according to the manu-
facturer’s instructions. DNA from each sample was then eluted in 120 μ l of eluting solution.
For blood samples genomic DNA was extracted from 2 ml of whole blood by FlexiGene DNA kit (Qiagen Inc., 
Valencia, CA, United States), following the manufacturer’s instructions. Concentration and purity index of each 
sample were evaluated by UV spectrophotometry as the ratio absorbance 260/280 nm; a purity index of 1.5–2.0 
was considered optimal.
Single nucleotide polymorphisms (SNPs) within each gene were selected using the Pupasuite software (http://
pupasuite.bioinfo.cipf.es/index.jsf - version 2.0.0, bioinfo 2008), the CIPF (Centro de Investigacion Principe 
Felipe) Single Nucleotide Polymorphism database (dbSNP) generated by the National Centre for Biotechnology 
Information (http://www.ncbi.nlm.nih.gov/SNP) and by review of the medical literature, using the following 
criteria:
(1) The polymorphism had some degree of likelihood to alter the structure or the expression of the gene in a 
biologically relevant manner;
(2) The minor allele frequency was above 10% (with the only exception of rs2305948, rs6877011 and rs307822);
(3) The genetic polymorphism was established and well-documented.
Further considerations led the selection of SNPs for our study. A correlation between the presence of a specific 
allele on a polymorphic site and the expression of the respective protein has been previously documented for 
VEGF.
Selected SNPs, chromosomal locations, positions and biological effects are summarised in Table 3.
SNP genotyping was performed by TaqMan technology, using SNP genotyping assay (Applied Biosystems, 
Foster City, CA). Polymerase chain reaction (PCR) was performed and genotypes were analysed on the 7300 
Real-Time PCR System (Applied Biosystems, Foster City, CA) using an ABI Prism 7300 Sequence Detection 
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System software (version 1.3.1, Applied Biosystems, Foster City, CA). Each reaction contained 0.2 μ l of total 
genomic DNA. Laboratory personnel blinded to patient status performed Genotyping, and a random 10% of the 
samples were repeated to validate genotyping procedures. All SNPs genotyped had to present an overall call rate 
of ≥ 90% to be included in our analysis, all samples resulted significant during the analysis and didn’t need test 
repetition.
Data Management and statistical Analysis. To detect a difference in the effect size (HR) with statis-
tical significance in the proportion of patients surviving at six months according to genotyping and assuming a 
6-month overall survival (OS) of 50% in an unselected regorafenib treated population and a 70% 6-month OS as 
a target, with α = 0.05 and β = 0.10, at least 121 patients were needed.
Statistical analysis was performed with MedCalc Statistical Software version 14.10.2 (MedCalc Software bvba, 
Ostend, Belgium; http://www.medcalc.org; 2014).
The association between categorical variables was estimated by Fisher exact test for categorical binomial varia-
bles or by chi-square test for all other instances. Survival probability over time was estimated by the Kaplan–Meier 
method.
Significant differences in the probability of survival between the strata were evaluated by log-rank test. Cox’s 
multiple regression analysis was used to assess the role of polymorphisms as prognostic factor adjusted for those 
variables resulted significant at univariate analysis. The Holm-Sidak correction18 was used to adjust the values 
for multiple comparisons. Tested variables included gender (male vs. female), median age (< 70 vs. ≥ 70 years), 
K-RAS or RAS status (wild type vs. mutant), ECOG performance status (0 vs. ≥ 1), previous lines for metastatic 
disease (≤ 3 vs. ≥ 4).
For statistical analysis, overall survival (OS) was defined as the time interval between the date of begin-
ning of regorafenib treatment to death or last follow-up visit for patients who were lost at follow-up, whereas 
progression-free survival (PFS) was defined as the interval between the date of beginning of regorafenib treat-
ment to death, first sign of clinical progression or last follow-up visit for patients who were lost at follow-up.
All genetic polymorphisms were examined for deviation from Hardy–Weinberg equilibrium using the 
Powermarker v.3.25 package (www.statgen.ncsu.edu/powermarker). LD analysis was also performed using the 
Powermarker v. 3.25 package. LD was estimated using r2, with r2 = 1 indicating complete LD and r2 = 0 indicating 
absent LD.
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SNP ID Gene
TaqMan catalog 
number Chr Chr. Position
Position in the gene/
Effect
Codon 
exchange aa. exchange
rs10434 VEGF-A C_1647360_20 6 43753212 3′ UTR(c) – –
rs2010963 VEGF-A C_8311614_10 6 43738350 5′ UTR(d) – –
rs25648 VEGF-A C_791476_10 6 43738977 Syn(a); ESE(b) TCC ⇒ TCT S [Ser] ⇒ S [Ser]
rs3025039 VEGF-A C_16198794_10 6 43752536 3′ UTR(c) – –
rs699947 VEGF-A C_8311602_10 6 43736389 Prom(e) – –
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rs6877011 VEGFR-3 FLT4 C_29057584_10 5 180029471 3′ UTR(c) – –
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